The results come as Dexcom is awaiting a decision from the Centers for Medicare and Medicaid Services to expand Medicare coverage of the devices for people with Type 2 diabetes.

The published study “reinforces the strength and totality of the data,” Leerink Partners analyst Mike Kratky wrote in a note to investors.

The study enrolled 440 people across 22 primary care practices in the U.S., randomly assigning 145 people to use Dexcom’s G7 CGM and 138 people to routine care. People in the CGM group saw their HbA1c levels decrease on average from a baseline 8.8% to 7.2%, while the control group saw a decrease from 8.7% to 8%.

The CGM group also spent five more hours per day in the target blood glucose range of 70 to 180 mg per deciliter.

The benefits were consistent across various demographics including age, sex, race and ethnicity, body mass index, diabetes duration, income, education, health insurance and the use of other glucose-lowering medications, Dexcom said in a summary of the results.

“The fact that almost all participants were still using CGM after 26 weeks and most were using it every day indicates that the participants recognized the benefit of CGM and incorporated it into their daily diabetes management,” Dr. Roy Beck, the study’s senior author and medical director of the JAEB Center for Health Research, said in a Dexcom statement.

Source link